Nick Beckett

Nick Beckett is a partner, Head of the CMS Cameron McKenna Intellectual Property team and Head of Lifesciences.

Nick has extensive experience in advising on all aspects of intellectual property. His practice spans both contentious and non-contentious issues in relation to trade mark, patent, design, copyright, passing off and confidentiality matters. He advises clients across a wide range of industry sectors including consumer products, information technology, high technology, engineering and pharmaceuticals. He also has substantial experience in the areas of parallel trade, anti-counterfeiting and trade mark and patent litigation spanning national borders.

Nick has advised numerous life-sciences clients on a variety of intellectual property issues, including seeking patent, supplementary protection certificate and other intellectual property protection, patent validity and infringement and other intellectual property considerations on corporate transactions. Nick is on the Research and Innovation Committee of the ABHI.

PLC Which Lawyer? recommends Nick for his work on repackaging and parallel trade.

Relevant experience includes advising:

• Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S. Read the press release.
• A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anticounterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices around Europe and bringing together a network to service the client's needs
• A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent
• Otsuka on all legal and regulatory issues associated with Otsuka's atypical antipsychotic product.  This entails acting as a central point of contact for the clients, managing the relationship and coordinating the provision of advice from our CMS European Network
• Leading Global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose
• US Corporation in a dispute concerning infringement and validity of the client's remediation patent for aquifers, also consideration of matters raised in EPO opposition procedure
• Large German high technology client in respect of alleged patent infringement concerning its German and United Kingdom traffic telematic business and its exploitation of new technology throughout Europe
• Budejovicky Metansky Pivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER
• Eli Lilly in the current leading pharmaceutical parallel trade repackaging case before the ECJ.
• Major US pharmaceutical company in disputes with numerous parallel traders
• A Nelson in landmark litigation regarding the Bach Flower Remedies trade marks
• Medical device company in relation to all intellectual property issues arising from licensing arrangements for a client involved in the manufacture of prosthetic limbs